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Abstract
We have developed the Voxel-Based Internal Dosimetry Application (VIDA) to provide patient-specific do-
simetry in targeted radionuclide therapy performing Monte Carlo simulations of radiation transport with the
Geant4 toolkit. The code generates voxel-level dose rate maps using anatomical and physiological data taken
from individual patients. Voxel level dose rate curves are then fit and integrated to yield a spatial map of
radiation absorbed dose. In this article, we present validation studies using established dosimetry results,
including self-dose factors (DFs) from the OLINDA/EXM program for uniform activity in unit density spheres
and organ self- and cross-organ DFs in the Radiation Dose Assessment Resource (RADAR) reference adult
phantom. The comparison with reference data demonstrated agreement within 5% for self-DFs to spheres and
reference phantom source organs for four common radionuclides used in targeted therapy (131I, 90Y, 111In,
177Lu). Agreement within 9% was achieved for cross-organ DFs. We also present dose estimates to normal
tissues and tumors from studies of two non-Hodgkin Lymphoma patients treated by 131I radioimmunotherapy,
with comparison to results generated independently with another dosimetry code. A relative difference of 12%
or less was found between methods for mean absorbed tumor doses accounting for tumor regression.
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Introduction
Radiation therapy using radiopharmaceuticals should beperformed with patient-individualized calculation of
doses to tumors and normal tissues that might express toxicity
or tumor control probability. Dosimetry using standardized
reference models based on the Radiation Dose Assessment
Resource (RADAR) schema has been established for many
years and is implemented in the OLINDA/EXM software.1
OLINDA/EXM provides some customization with the ability
to adjust reported doses for patients’ specific organ masses.
However, the use of standardized phantoms has two major
shortcomings when applied to patient dosimetry for targeted
radionuclide therapy (TRT). The dosimetric quantity re-
ported, mean absorbed dose to a target organ, assumes uni-
form activity in the source region(s). Evidence indicates that
deterministic biological effects including tumor response and
normal tissue toxicity are not well predicted by the mean
absorbed dose and may be significantly influenced by non-
uniform doses and temporally changing dose rates.2 Also,
although OLINDA/EXM allows calculation of self-dose to
unit density spheres, which might be used to estimate tumor
dose estimates, contributions to tumor dose from other organs
and tissues cannot be included. Dose contributions to and
from distant regions due to high energy photons may be non-
negligible for radionuclides with significant c emissions.3
Many of the limitations with using fixed-geometry meth-
ods for dose calculations in TRT can be overcome using
image-based techniques. It is generally accepted that voxel-
based dosimetry incorporating the spatial and temporal dis-
tribution of activity from sequential SPECT provides greater
accuracy and permits assessment of tumor dose–response
and normal tissue toxicity. Image-based approaches to patient-
individualized dosimetry have been demonstrated by several
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groups, including 3D-ID,4 updated to include radiobiologi-
cal dose assessment as 3D-RD,5,6 SIMDOS,7 RMDP,8 and
an adaptation of dose planning method (DPM).9 These
codes employ various methods for photon and electron
transport, including point kernel convolution and Monte
Carlo (MC) simulation. They generally rely on manual
segmentation of the patient anatomy and quantitative spa-
tial distributions of activity to produce three-dimensional
(3D) maps of radiation dose and dose-volume histograms
(DVHs). This approach not only provides improved results
compared with fixed geometry dosimetry with standardized
phantoms, but also takes considerable time and effort to
perform.
Here, we describe the development of voxel-based in-
ternal dosimetry application (VIDA), a 3D image-based
dosimetry technique using the Geant4 MC tool kit for voxel-
by-voxel absorbed dose calculation. Geant4’s radioactive
decay module provides a general method for assessing dose
from any type of radionuclide through direct sampling of the
decay scheme. VIDA was validated using two independent
techniques. The first method applies a simple geometry of a
spherical source in a semi-infinite scattering medium. The
self-dose to spheres of various masses was determined as-
suming a uniformly distributed activity. The second ap-
proach compares dose factors (DFs) for selected target
organs in a standard male reference phantom assuming
uniform activity in the source organ. In addition, VIDA was
used to estimate doses from SPECT studies of two patients
with non-Hodgkin lymphoma (NHL), with comparison of
our results to those calculated previously with another 3D
dosimetry code.
Materials and Methods
VIDA allows for patient-specific dosimetry methods by
coupling 3D anatomical data (CT) with functional images
(SPECT or PET). The application consists of two main
components (Fig. 1), the Geant4 simulation code to generate
3D maps of voxel-level absorbed energy and a custom ex-
ponential fitting tool for radiopharmaceutical kinetics
modeling developed in MATLAB. Detailed descriptions of
these two elements of VIDA and the methods used to val-
idate the application follow.
MC simulation
Geant410,11 is an open source, integrated radiation transport
package that simulates many particle types and their inter-
actions based on a user-specified geometry. Particle interac-
tions are tracked through materials in the simulation
environment and energy deposition is scored in selected tar-
get regions. VIDA was created from an existing application
that traced mono-energetic photons and electrons uniformly
distributed in a standard anthropomorphic phantom.12
The material definitions implemented in VIDA include
air, soft tissue, lung, and whole skeleton (Table 1) derived
from data tabulated in ICRU Publication 46 Appendix A.13
The simulation geometry and voxel materials are defined by
an organ identification map constructed from one of two
methods. Organs of interest and tumor volumes can be
outlined on the patient CT using conventional segmentation
methods. For multiple time points, manual segmentation of
each CT can be time-prohibited and tissue maps of relevant
materials can be quickly created for simulation using den-
sity thresholds. Organ identification can also be defined by
a patient-specific anatomical model produced from Non-
Uniform Rational B-Spline (NURBS) standard phantoms.14,15
The NURBS phantom is rendered over the CT images and
custom transformation algorithms are applied to morph the
body contour and organ surfaces to match patient anat-
omy. The deformed NURBS model is then converted to
voxel format matching the resolution of the quantitative
activity images. The method of quick adaption of an exist-
ing body model to an individual patient and its usefulness
in patient-specific dosimetry will be reported a separate
publication.
Decay events are generated voxel-by-voxel based on an
activity map from quantitative SPECT or PET imaging. Events
created inside each voxel are assumed uniformly distrib-
uted and assigned a random position and direction vector.
FIG. 1. VIDA procedure
flow with key components
and inputs. 3D, three-
dimensional; MC, Monte
Carlo; VIDA, voxel-based
internal dosimetry
application.
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VIDA employs the radioactive decay module in Geant4 to
produce primary particles using data including branching
ratios, decay energies and transition probabilities, and en-
ergies for nuclear de-excitation. A detailed overview of the
radioactive decay package is found in Sauf et al.16 The
physics models implemented in VIDA are a modified ver-
sion of the standard electromagnetic package with options to
improve electron particle transport. The energy interval in
VIDA was set from 10 eV to 50MeV and divided into 220
bins to increase the sampling of interaction cross sections for
particle energies in targeted therapy. Atomic de-excitation
processes, including Auger emissions, were activated to
handle atomic shell vacancies.
The energy deposited due to primary decay, secondary
particles, and subsequent c emission from isomeric transitions
is tallied for each voxel. The voxel-level deposited energy is
used to create 3D dose rate maps that are integrated over time
to produce DVHs and average whole organ doses. VIDA is
compiled using Geant4 9.4 and is run on the Vanderbilt
University multi-node Advanced Computing Center for Re-
search and Education (ACCRE) with the capability of being
split into multiple parallel jobs for decreased run-time. For a
geometry matrix of 256· 256· 80, simulation of one million
decay events requires*3 hours of CPU time and 300 MB of
memory on a 2.3-GHz Nehalem processor (Intel).
Exponential fitting
Patient kinetics modeling is performed by the exponential
fitting module in VIDA. This module (Fig. 2) consists of a
MATLAB-based graphical user interface for curve fitting by
iterative least squares estimation using the nonlinear re-
gression model in the Statistics Toolbox (Release 2012a).
The user has a choice of fit functions depending on uptake
kinetics and number of sequential scans. Instantaneous ac-
tivity uptake, resulting in exponentially decaying dose rates,
can be fit to a mono-exponential or bi-exponential function
of the general form:
_D(t)¼ _D1e k2tþ _D2e k2t
Initial guesses for the rate components ( _D1 and _D2) are de-
rived from the time-sequence data and elimination constants
(k1 and k2) from the physical half-life of the radionuclide of
interest. The fitting algorithm automatically detects voxels
with noninstantaneous uptake (i.e., tumor) and fits these data
to a bi-exponential including the (0, 0) point of the form:
_D(t)¼ _D0(e k2t  e k2t)
The voxel dose is computed by integration of the fitted
function based on a time interval supplied by the user, with a
default range of zero to infinity.
The exponential fitting tool in VIDA provides the user
with several other options. The user may choose to fit the
entire body in the image field of view or select specific
organs and tumors based on the organ map. Also, the user
may specify the resolution of the resulting dose map. A
scaled map with voxel dimensions twice as large in the
transverse plane is created by fitting a voxel dose curve to
the data in the corresponding 2 · 2 · 1 cell in the original
array. This option decreases the overall processing time and
may facilitate regression convergence when data are only
available for a limited number time points.
Evaluation tools are provided by the exponential fitting
module to assess the results. The user can plot a histogram
of the coefficients of determination (R2) for all fitted voxels.
Fits with R2 values below a user-defined threshold may be
refined by rerunning the regression using an array of dif-
ferent initial coefficient values to optimize R2. The user can
also evaluate the dose results in a three plane viewer and
plot the data and fitted curve for a selected voxel.
Dose to uniform activity spheres
VIDA was used to determine DFs in unit-density spheres
ranging in size from 10 to 1000 g. For consistency with
patient modeling, each sphere was ‘‘voxelized’’ into an
array large enough to include the surrounding scattering
medium. Spatial resolution was chosen to limit the error
in sphere mass from digitally approximating the surface
to less than 0.5%. The spheres were defined as tissue-
equivalent material surrounded by a scattering medium of
water. Tissue composition was taken from MIRD Pamph-
lets 3 and 817,18 to facilitate comparison to previously
published results.
Uniform activity was simulated for common radionu-
clides used in targeted internal therapy including 90Y, 131I,
111In, and 177Lu. For each simulation, 1 million events were
tracked resulting in absorbed energies within the sphere with
relative errors of less than 0.5%. Relative error is defined as
the 1r standard deviation of the tally (energy deposited)
divided by the average tally.19 Self-DFs were calculated and
compared to the unit density sphere model in OLINDA/
EXM.1
Table 1. Material Definitions in Voxel-Based Internal Dosimetry Application Monte Carlo Simulation
Chemical composition (% by mass)
Material Density (g/cm3) H C N O Elements Z > 8
Air 0.00121 — 0.01 75.53 23.18 Ar (1.28)
Soft tissuea 1.03 10.5 25.6 2.7 60.2 Na (0.1), P (0.2), S (0.3), Cl (0.2), K (0.2)
Lungb 0.26 10.3 10.5 3.1 74.9 Na (0.2), P (0.2), S (0.3), Cl (0.3), K (0.2)
Whole skeletonc 1.35 6.5 28.6 3.6 41.7 Na (0.1), Mg (0.1), P (5.9), S (0.2), Cl (0.1),
K (0.1), Ca (13.2), Fe (0.1)
aAverage adult male.
bAdult healthy, inflated.
cComposite material defined using average density and elemental compositions of adult whole bones (excluding cranium and mandible).
18 KOST ET AL.
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Organ S values in adult male phantom
DFs for selected organs were determined using the RA-
DAR reference adult male phantom12 (Fig. 3). The phantom
anatomy is a modified version of the NURBS-based cardiac-
torso (NCAT) phantom14,15 with ICRP publication 8920
adult male reference organ masses. An organ map was
created by rendering the phantom in voxel format with
resolution of 1.5 · 1.5 · 5.0mm. Any voxels outside of the
boundary of the phantom were defined as air. Instead of
using the default materials defined in Table 1, simulation
materials were changed to the densities and compositions of
soft tissue, lungs, and bone21 used to generate new specific
absorbed fractions (SAFs)12 to aid comparison between our
results and the reference data.
Simulations were performed for the same radionuclides as
the uniform spheres (90Y, 131I, 111In, and 177Lu) with three
different organs designated as the source of radioactivity
(liver, spleen, and pancreas). These organs were chosen as
representative sources centrally located in the body with
varying shape. Each run generated 5 million decay events
uniformly throughout the source organ, resulting in relative
errors of less than 2% in the total energy deposited in each
target volume. DFs were determined using the average dose
deposited in each target organ and compared to reference
data. Target volumes included the three source organs and
also the lungs and kidneys to evaluate self-dose and cross-
organ doses to distant structures that may be of interest in
TRT dosimetry.
Radioimmunotherapy patient dosimetry
Individualized dosimetry was performed for two follicu-
lar NHL patients treated with 131I-labeled tositumomab
(Bexxar) using multiple SPECT/CT scans. These patients
provided written informed consent for the additional
FIG. 2. Screen capture of
MATLAB-based exponential
fitting tool in VIDA.
FIG. 3. Anterior views of the RADAR adult male NURBS
phantom. NURBS, Non-Uniform Rational B-Spline;
RADAR, Radiation Dose Assessment Resource.
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SPECT/CT scans not included in the normal treatment
protocol. The clinical treatment protocol has been previously
described in the literature22 and is briefly outlined here. Each
patient was imaged at three time points after administration
of a diagnostic tracer of 185MBq. Therapeutic doses of
3.74GBq (patient 1) and 3.43GBq (patient 2) were admin-
istered to deliver a nominal whole-body absorbed dose of
75 cGy based on post-tracer imaging. Patients were imaged
at three time points post-therapy, with a delay for the first
scan of *48 hours due to dead time and exposure consid-
erations (patient 1, 47.5 hours; patient 2, 48.58 hours). Ad-
ditional details of image acquisition, reconstruction, and
activity quantification are included elsewhere.22–24
Voxel-based dosimetry. VIDA was used to obtain a dose
rate map at each time point. A map defining different ma-
terials for simulation (Table 1) was automatically generated
from the CT images in a preprocessing step using MA-
TLAB. Density maps were created using calibration of HUs
to material density as a bi-linear fit based on data from
Schneider et al.25 Air was defined for voxel densities less
than 0.15 g/cm3, lung by a range of 0.15 to 0.61 g/cm3, soft
tissue between 0.61 and 1.17 g/cm3, and whole bone greater
than 1.17 g/cm3. Activity maps were sampled using 20
million events, resulting in relative errors in the deposited
energy of less than 1% in whole organs and a maximum of
10% for individual voxels in the tumor and organs of in-
terest. No partial volume correction (PVC) was performed,
as tumor volumes exceeded 100mL. The voxel-tallied en-
ergy deposited was converted to absorbed dose using voxel
masses derived from the simulation tissue densities. In-
stantaneous dose rate maps per administered activity were
generated by scaling the dose deposited in each voxel by the
ratio of actual field-of-view activity to simulated activity.
Target definition and image registration. Tumors and
normal tissue organs were segmented on the high resolu-
tion first post-tracer CT image (512· 512· 196 matrix,
0.977 · 0.977· 2.0mm voxel size) using a combination of
manual and semi-automatic segmentation techniques in-
cluded in the ITK/SNAP toolkit.26 Normal organ volumes
were verified and tumors were identified by a subspecialty
radiologist with experience in both body CT and nuclear
medicine.
CT-based registration of serial dose rate images was
performed with an affine rigid registration algorithm based
on maximizing mutual information27 developed by the
Vanderbilt University Institute of Imaging Science. The CT
images were down-sampled to a resolution of 256· 256 · 78
(1.954 · 1.954· 5.0mm) to match the slice thickness of the
SPECT data and to expedite registration. The CT image set
of the first post-tracer scan was assigned to be the reference
image in the registration algorithm. All other time points
were registered to the reference image by first performing
CT–CT registration and applying the transformation matri-
ces to the corresponding dose rate maps.
Conversion to 3D absorbed dose. Each 3D deposited
energy map from the MC simulation was converted to an
instantaneous dose rate map using voxel masses calculated
from the materials in Table 1. Voxel-level dose rate curves
were fit to a mono-exponential decay function for both the
pretherapy tracer data and the post-therapy scans using
the exponential fitting tool in VIDA. An absorbed dose
map with voxel dimensions of 3.908· 3.908 · 5.0mm3
(128 · 128· 78 array) was generated using the option to fit
voxel curves to the corresponding 2· 2 · 1 cell array of the
higher resolution dose rate maps. This resolution was chosen
to improve processing time without affecting accuracy due
to the already limited resolution of the SPECT camera (full
width at half maximum £ 3.9mm).
Tumor dosimetry. Malignant lymphomas can be highly
sensitive to radiation, leading to measurable changes in vol-
ume within the first few days of treatment.28 The effect of
tumor regression on absorbed tumor dose was investigated by
defining tumor volumes of interest (VOIs) on the CT at each
time point. The average absorbed tumor dose was calculated
by fitting the volume-adjusted dose rate curve. A comparison
was made to mean absorbed tumor doses from the DPM MC
software9,22,29 using the same tumor VOIs to minimize error
due to differences in segmentation between institutions.
FIG. 4. Dose factors com-
parison between VIDA and
OLINDA/EXM for unit den-
sity soft tissue spheres of
different masses.
20 KOST ET AL.
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Results
Dose to uniform activity spheres
DFs for self-dose to uniform activity spheres are shown in
Figure 4. The differences between VIDA and OLINDA/
EXM (Table 2) ranged from 0.4% to 5%, with the largest
deviations occurring in the smallest sphere. DFs for 90Y
show the largest difference between the two models with a
range of 2%–5%.
Organ DFs in the adult male phantom
Results for the reference phantom study are presented in
Table 3. Cross-organ DFs are omitted for 90Y because b-
emission energy is mostly absorbed locally. Any dose de-
posited in target regions far from the source organ is mainly
due to bremsstrahlung radiation and results in low scoring
statistics. Deviations in the DFs for organ self-dose ranged
between 0.6% and 5%. The difference in cross-organ DFs
spanned from 0% to 9% with lower VIDA results compared
with OLINDA/EXM for almost all source-target organ pairs.
Radioimmunotherapy patient dosimetry
SPECT/CT images with tumor outlines and resulting dose
maps for each patient are shown in Figure 5. Tumor DVHs
Table 2. Relative Percent Differences
in Voxel-Based Internal Dosimetry Application
and OLINDA/EXM Sphere Dose Factors
Mass (g) Diameter (cm) 131I 90Y 111In 177Lu
10 2.7 - 1.4 - 5.0 3.8 - 1.3
20 3.4 - 0.9 - 4.1 3.8 - 0.9
100 5.8 - 0.9 - 2.5 2.8 - 0.7
400 9.1 - 0.9 - 2.3 0.9 - 0.7
1000 12.4 - 0.5 - 2.1 0.4 - 0.4
Relative % difference defined as 100· (DFVIDA -DFOLINDA)/
DFOLINDA. DF, dose factor.
Table 3. Dose Factors for Source and Target Organs in the Radiation Dose Assessment
Resource Adult Male Phantom
Organ DF (mGy/MBq-s)
VIDA OLINDA % Diff a VIDA OLINDA % Diff a
Source Target 131I 90Y
Liver Lungs 8.05E–07 8.09E–07 - 0.5 — — —
Liver 2.27E–05 2.28E–05 - 0.4 7.89E–05 8.05E–05 - 2.0
Kidneys 1.11E–06 1.14E–06 - 2.7 — — —
Spleen 3.05E–07 3.29E–07 - 7.6 — — —
Pancreas 1.09E–06 1.11E–06 - 1.8 — — —
Spleen Lungs 4.67E–07 4.70E–07 - 0.6 — — —
Liver 3.07E–07 3.16E–07 - 2.9 — — —
Kidneys 2.40E–06 2.36E–06 1.7 — — —
Spleen 2.35E–04 2.32E–04 1.3 9.16E–04 9.26E–04 - 1.1
Pancreas 1.35E–06 1.36E–06 - 0.7 — — —
Pancreas Lungs 5.36E–07 5.62E–07 - 4.7 — — —
Liver 1.08E–06 1.13E–06 - 4.5 — — —
Kidneys 8.31E–07 8.84E–07 - 6.2 — — —
Spleen 1.35E–06 1.43E–06 - 5.8 — — —
Pancreas 2.44E–04 2.49E–04 - 2.0 9.49E–04 9.94E–04 - 4.6
111In 177Lu
Liver Lungs 8.80E–07 8.92E–07 - 1.4 9.57E–08 8.93E–08 6.9
Liver 1.01E–05 9.91E–06 1.9 1.35E–05 1.36E–05 - 0.7
Kidneys 1.23E–06 1.27E–06 - 3.2 1.16E–07 1.18E–07 - 1.7
Spleen 3.16E–07 3.47E–07 - 9.4 2.84E–08 3.12E–08 - 9.4
Pancreas 1.20E–06 1.24E–06 - 3.3 1.12E–07 1.14E–07 - 1.8
Spleen Lungs 5.04E–07 5.05E–07 - 0.2 4.68E–08 4.64E–08 0.9
Liver 3.17E–07 3.34E–07 - 5.1 2.82E–08 3.03E–08 - 7.2
Kidneys 2.65E–06 2.65E–06 0.0 2.69E–07 2.58E–07 4.2
Spleen 7.58E–05 7.19E–05 5.3 1.60E–04 1.59E–04 0.6
Pancreas 1.48E–06 1.50E–06 - 1.3 1.41E–07 1.41E–07 0.0
Pancreas Lungs 5.80E–07 6.11E–07 - 5.2 5.41E–08 5.67E–08 - 4.7
Liver 1.20E–06 1.27E–06 - 5.7 1.10E–07 1.16E–07 - 5.3
Kidneys 9.13E–07 9.81E–07 - 7.2 8.55E–08 9.16E–08 - 6.9
Spleen 1.48E–06 1.58E–06 - 6.5 1.41E–07 1.49E–07 - 5.5
Pancreas 7.95E–05 7.81E–05 1.8 1.66E–04 1.70E–04 - 2.4
aRelative difference defined as 100· (DFVIDA -DFOLINDA)/DFOLINDA.
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(Fig. 6) were generated using volumes from the first post-
tracer scan. The first post-tracer time point, scaled by the ratio
of activity administered for the therapy and tracer studies,
was included in the therapy data set due to the lack of an early
imaging time point. Mean absorbed doses to tumor and or-
gans were calculated and compared to results from DFs de-
rived from the RADAR adult male reference phantom12 and
the unity density sphere model (Table 4). Organ doses are
reported only if the entire volume was included in the field of
view. Reference doses were adjusted for differences in organ
masses between the patient and phantom.
Between the initial tracer study and the last imaging point
post-therapy, significant decreases in both tumor volumes
occurred (Table 5). When accounting for shrinkage, the
tumor dose differed as much as 16% compared with the
mean absorbed dose to a static volume. The comparison of
mean tumor doses accounting for changing volume between
VIDA and DPM agree within 12% or less.
Discussion
There has been significant focus on developing methods of
image-based 3D dose calculations with the goal of providing
patient-specific dosimetry for internal therapy. We have cre-
ated VIDA, an application designed for individualized do-
simetry using the Geant4 toolkit. In the simulation, patient
FIG. 5. Fused SPECT/CT images for patient 1 (A) and patient 2 (B)withmatching 3D dosemaps overlaid onCT for patient 1
(C) and patient 2 (D). The dose maps are displayed in units of Gy. Color images available online at www.liebertpub.com/cbr
FIG. 6. Tumor dose-volume histograms from tracer and therapy scans for patient 1 (A) and patient 2 (B). The tumor
volumes were taken from the first post-tracer scan.
22 KOST ET AL.
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geometry is represented by a 3D map of integer organ iden-
tification numbers instead of assigning voxel density and
composition directly from CT images as done in the Geant4
DICOM application. The reasoning for this approach is to
permit modeling patient anatomy using a NURBS-based
deformable phantom that can be digitized to a 3D organ map.
For multiple time points, tissue maps using density thresholds
can be quickly created for simulation purposes in a pre-
processing step such as those used in the RIT patient studies.
We believe our approach of implementing uniform density
organs based on a map of identification numbers offers ade-
quate flexibility for tissue definition and introduces negligible
uncertainty in particle transport compared to other sources of
errors in the dose estimates.
VIDA was designed to generate dose rate maps at each
time point for voxel-based integration of the total absorbed
dose. Although this technique requires additional simulations,
the rational for this approach is twofold. The determination of
instantaneous dose rates permits inclusion of tumor regres-
sion over scan times in the absorbed dose estimates. Also,
incorporation of radiobiological models requires 3D absorbed
dose rate images at each time point rather than the simula-
tion of absorbed dose from a single map of cumulated activity.
A similar approach of generating multiple dose rate maps
has been implemented in other dosimetry studies.22,24,29–31
However, if desired, the user can use the exponential fitting
tool in VIDA to create a map of cumulated activity for input
in the MC simulation to determine the integrated dose in each
voxel with only one run.
Due to the inherent flexibility of MC simulation tools such
as Geant4, verification of the results is of the utmost impor-
tance. Efforts relating to the validation of Geant4 have been
extensively published and include topics relevant to our ap-
plication such as radioactive decay simulation32 and elec-
tromagnetic processes of low energy electrons.33 Here, VIDA
was validated under several conditions including dose to
uniform activity spheres and organ DFs from various sources
in an anthropomorphic phantom and was achieved excellent
concordance between our results and reference data.1,34
The agreement in DFs for the spheres was within 5% and
improved with increasing mass, due to the decreased likeli-
hood of an electron escaping the source volume before
complete energy absorption. For all sphere sizes, the largest
differences occurred for 90Y, a pure b emitter. The discrep-
ancy is most likely due to different methods used to sample
the b energy spectrum. OLINDA/EXM applies a single SAF
for the average energy of the b emission spectrum, whereas b
particles created in a decay event in Geant4 are assigned
energies by sampling the b-Fermi-function.16 b emissions
with energy higher than the spectrum mean have a longer
range in tissue and higher interaction likelihood; however,
there is also an increased possibility of these electrons exiting
the sphere without being scored, which results in less total
energy absorbed reflected by the lower DFs from VIDA.
For radionuclides that undergo b decay (131I, 90Y, and
177Lu), DFs calculated from VIDA for spheres and the
majority of source/target pairs in the reference phantom are
slightly lower compared with OLINDA/EXM. However, all
self-DFs from VIDA are higher for 111In. 111In decays by
electron capture and dose is locally deposited by low energy
Auger electrons and small yield internal conversion elec-
trons. The difference in 111In self-DFs may be due to error in
the interpolation of SAFs for the very low energy Auger
electrons by OLINDA/EXM and improved low energy
electron transport models in Geant4 compared to MNCP4B;
nonetheless, the differences are small.
Several other groups have performed simulations for in-
ternal radiotherapy using Geant4. Amato et al. reported
absorbed fractions for monoenergetic photons and elec-
trons in ellipsoids.35,36 Using these data, they specified the
Table 4. Voxel-Based Internal Dosimetry
Application and Radiation Dose Assessment
Resource Reference Mean Absorbed Doses
to Organs and Tumors and Percent Differences
(in Parentheses) from Post-Therapy Dosimetry
Patient 1 Patient 2
Organ
VIDA
dose
(cGy)
RADAR
dose
(cGy)
VIDA
dose
(cGy)
RADAR
dose
(cGy)
Lungs — — 221 254 (- 13%)
Heart 411 438 ( - 6%) 311 380 (- 18%)
Spleen 186 191 ( - 3%) 183 160 (14%)
Liver 223 210 (6%) — —
Kidneys 190 160 (19%) — —
Tumor 196 187 (5%) 150 135 (11%)
Relative difference defined as 100· (DVIDA -DRADAR)/DRADAR.
RADAR, Radiation Dose Assessment Resource.
Table 5. Comparison of Mean Absorbed Tumor Doses Between Voxel-Based Internal
Dosimetry Application and Dose Planning Method
Patient 1: abdominal tumor Patient 2: Lt. axillary tumor
Initial tumor volume (mL) 269 226
Total tumor shrinkage 53% 23%
VIDA DPM VIDA DPM
Predicted dose, static vol. (cGy) 291 — 153 —
Predicted dose, changing vol. (cGy) 292 261 (12%) 154 164 ( - 6.1%)
Delivered dose, static vol. (cGy) 196 — 150 —
Delivered dose, changing vol. (cGy) 252 266 ( - 5.3%) 151 162 ( - 6.8%)
Relative difference defined as 100· (DVIDA -DDPM)/DDPM.
DPM, dose planning method.
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average energy deposited per disintegration of 131I as a
function of the generalized radius. The energy deposited per
disintegration of 131I by VIDA for the two smallest spheres
(10 and 20 g) was 201 and 205 keV respectively. These
energies are in excellent agreement with Amato et al. for
ellipsoidal sources with generalized radii of 1.34 cm
(201 keV) and 1.68 cm (206 keV).36 A 3D dosimetry appli-
cation RAYDOSE37 uses the General Particle Source to
create spatial distributions of decay events slice by slice
based on patient PET images. RAYDOSE was validated us-
ing DFs for water spheres based on imaging a phantom
containing activity-filled spheres of various sizes. For 131I and
177Lu, RAYDOSE DFs were within 1%–3% of OLINDA/
EXM and agree with the evaluation of VIDA and OLINDA/
EXM for spheres of comparable sizes. Although RAYDOSE
and VIDA are similar applications, we were unable to com-
pare organ DFs and patient-specific doses because RAY-
DOSE has only been validated based on activity distributions
in physical phantoms and has not yet been applied to clini-
cal patient studies. Another Geant4 dosimetry application
GRNT38 uses the command line interface to define phantom
geometry, simulation materials, and the particle emission
spectrum. GRNT was validated by comparing organ DFs
from the MIRD-5 phantom to RADAR reference data. The
relative differences found using GRNT for liver as the source
organ were *5% for self-DFs and 1%–10% for cross-organ
DFs to the kidneys, lungs, pancreas, spleen for 131I and 90Y,
which are similar to those from VIDA.
To assess VIDA’s treatment of nonuniform activity distri-
butions and clinical utility, SPECT-based tumor and organ
dosimetry was performed for patients receiving 131I radio-
immunotherapy. Patient mean absorbed organ doses were
compared to doses from a reference phantom with relative
differences less than 20% (Table 4). The differences could be
caused by several different factors. The reference dose cal-
culations were performed based on activity in user-specified
source organs. Activity in the rest of the field of view was
assigned to the body remainder. The dose to target organs from
the body remainder activity is calculated based on a uniform
distribution of this activity spread across the entire volume in
the phantom (including arms and legs). Thus, we would expect
the reference organ doses to be lower compared to VIDA
where dose is deposited from activity in the field of view closer
to the target organs. Also, there are slight differences in the
material densities and compositions in VIDA compared to
those used to generate the SAFs for the RADAR reference
phantom. The lung density is lower in VIDA by more than
10%, which may account for the underestimation of lung dose
for patient 2. Tumor doseswere also compared to self-irradiation
doses using the uniform sphere model in OLINDA/EXM. As
expected, the tumor doses from VIDA are larger by 5%–11%
due to the contribution from the remaining body.
Tumor DVHs were generated based on the predicted and
delivered dose maps (Fig. 6). Tumor volumes were defined
based on segmentation of CT from the first post tracer scan.
It is difficult to assess the impact of tumor regression on 3D
dose heterogeneities, and mass changes across the imaging
time period were not incorporated in the DVHs. Both patients
exhibit more conformal dose distributions for the delivered
tumor dose compared with the tracer-predicted distribution.
The maximum delivered dose is also lower compared with
the predicted DVH. One possible explanation for these dif-
ferences is an increased antibody clearance in tumor cells
after treatment due to radiobiological damage caused by the
tracer dose, as previously suggested by Eary et al.39
When we account for changes in tumor volumes, the
tracer-predicted tumor doses concur with the delivered
therapeutic dose within 16%. For both patients, the tracer
scans over-predict the delivered dose, although the differ-
ence for patient 2 is very small. This trend is consistent with
a previously reported study.22 The therapy-delivered mean
absorbed doses were compared to results from DPM MC
using the same tumor volumes. With the exception of the
tracer study for patient 1, the tumor doses from VIDA are
lower by 5%–7% compared to DPM. Our dose rates for the
changing tumor volumes were derived from mean values
from the 3D energy deposited maps for the tumor VOI de-
fined at each time point. These volume-averaged dose rates
were fit to a bi-exponential curve and directly integrated to
determine the mean tumor dose. In comparison, the calcu-
lation of the mean tumor-absorbed dose using DPM in-
volves a piecewise integration of the absorbed dose rates
over three time periods using a mixed model fit.40 These
varying approaches may account for the discrepancies in
tumor dose, even though the differences in tumor absorbed-
dose rates between the two simulations were less than 2%.
Many contributing factors make estimating the uncer-
tainty in organ and tumor doses for patient studies difficult.
When performing voxel-based patient dosimetry using MC,
there are many sources of error including the quantification
of the activity distribution, the fidelity of the registration
process between the serial SPECT/CT scans, and the ability
to properly define organ and tumor volumes. Also, fitting
voxel dose rates with a limited number of time points may
introduce additional uncertainty. Acquisition of more than
three sequential SPECT scans post-tracer or post-therapy
administration would aid the fitting process but may be
prohibitive in the clinical environment.
The 3D OSEM reconstruction methods used for the patient
studies in this work have produced quantitative results within
10% for volumes 16mL and larger without PVC.23 Fur-
thermore, the organ and tumor volumes in the patient studies
presented here are sufficiently large, preventing partial vol-
ume effects from being a significant source of error in
estimates of the average absorbed dose. MIRD Pamphlet 23
recommends PVC for objects less than dimensions of
3·FWHM of the spatial resolution of reconstructed images,
but currently a well-validated method for voxel-based cor-
rections for SPECT has yet to be developed.41 Therefore,
voxel-level PVC was not applied before using the activity
distributions in VIDA. To mitigate the uncertainty in reported
doses due to partial volume effects, we limited the voxel
resolution of the 3D dose map to 3.908· 3.908· 5mm3, a
factor of four larger than the original reconstructed image
resolution and on the order of the intrinsic FWHM of the
SPECT system used to acquire the data.
Image registration accuracy for 3D internal dosimetry has
been discussed previously.42–44 Availability of high resolu-
tion co-registered SPECT/CT images in our patient studies
permitted CT-based registration. Thus, possible errors in
SPECT-SPECT registration from poor spatial resolution
and temporal variability in the activity distributions were
avoided. A mutual information rigid registration algorithm
was used in this study. Nonrigid techniques have been shown
24 KOST ET AL.
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to provide the most robust results; however, only small dif-
ferences in doses for volumes of interest were found between
rigid and nonrigid registration.44 Nonetheless, rigid registra-
tion may affect the accuracy of the 3D dose to the axillary
tumor in patient 2, as nonrigid movements are more likely to
occur in the neck and shoulder region of the body. An effort
to quantify the effects of mis-registration on 3D patient dose
was beyond the scope of this study.
Organ segmentation may also contribute to the uncertainty
in reported doses. Errors in structure are typically small
compared with those from image registration; however, ero-
sion or dilation of the volume by only one voxel can con-
tribute as much of 7% difference in activity.42 Because
volume of interest definition is typically a subjective task
reliant on human observation, it is difficult to predict the true
magnitude of the error. The tumor volumes were identical in
VIDA and DPM to avoid segmentation uncertainties in our
relative dose comparisons, but no assessment was done to
determine the error in the defined volumes outlined by the
radiologist compared to the true physical volumes.
Recent emphasis has been placed on not only calculating
3D absorbed doses (Gy) in TRT, but also the biological re-
sponse of different tissues considering the dose rates being
delivered, and tissue-specific radiosensitivity parameters.5,24,30
This research describes our initial work to develop and vali-
date a functioning dosimetry program for our use; in future
development of the code we hope to include consideration
of radiobiological parameters.
Conclusion
Wehave developedVIDA, an application for patient-specific
dosimetry in targeted therapy using the Geant4 MC toolkit to
model radiation absorption in tissue from internal emitters. The
simulation generates voxel-level dose rate maps based on ana-
tomical and quantitative functional imaging. It has been
benchmarked with results using the RADAR formalism in-
cluding self-DFs for uniform activity spheres and organ self-
dose and cross-organ doses in a standard phantom. VIDA has
been applied to patient studies for 131I radioimmunotherapy for
NHL, with tumor doses that are in excellent agreement with
results from theDPMMCalgorithm.The future aimof thiswork
is to employ VIDA in conjunction with patient-specific organ
maps created from a deformable NURBS anatomical model.
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